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Abstract
Deriving mechanisms of immune-mediated disease from GWAS
data remains a formidable challenge, with attempts to identify
causal variants being frequently hampered by strong linkage dise-
quilibrium. To determine whether causal variants could be identi-
fied from their functional effects, we adapted a massively parallel
reporter assay for use in primary CD4 T cells, the cell type whose
regulatory DNA is most enriched for immune-mediated disease
SNPs. This enabled the effects of candidate SNPs to be examined
in a relevant cellular context and generated testable hypotheses
into disease mechanisms. To illustrate the power of this approach,
we investigated a locus that has been linked to six immune-
mediated diseases but cannot be fine-mapped. By studying the
lead expression-modulating SNP, we uncovered an NF-jB-driven
regulatory circuit which constrains T-cell activation through the
dynamic formation of a super-enhancer that upregulates TNFAIP3
(A20), a key NF-jB inhibitor. In activated T cells, this feedback
circuit is disrupted—and super-enhancer formation prevented—by
the risk variant at the lead SNP, leading to unrestrained T-cell acti-
vation via a molecular mechanism that appears to broadly predis-
pose to human autoimmunity.
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Introduction
Hundreds of genetic loci have been implicated in autoimmune and
inflammatory diseases, but the mechanisms by which these effect
diseases remain largely unknown (Claussnitzer et al, 2020). An
important first step in uncovering these mechanisms is to refine
genetic associations down to specific causal variants, whose biologi-
cal effects mediate disease risk, but statistical attempts to do this
have been frustrated by linkage disequilibrium (LD), with only a
minority of loci being resolved (Farh et al, 2015; Huang et al, 2017).
Other methods have sought to re-weight candidate SNPs using their
enrichment within functional genomic elements (e.g. tissue-specific
regulatory marks; Schaub et al, 2012; Shooshtari et al, 2017), but
these do not assess whether SNPs have functional consequences,
nor reveal the biological effect that contributes to disease. This
leaves the majority of GWAS loci either unresolved or unresolvable,
and the ambition of identifying disease mechanisms largely unre-
alised (Visscher et al, 2017). To compound this challenge, the speci-
fic gene(s) that are affected by disease-associated variants have not
been confirmed for most loci (Claussnitzer et al, 2020). Many asso-
ciated haplotypes, for example, contain multiple genes with little
evidence for any one being causally involved, while other associa-
tions are entirely located within intergenic regions (or “gene
deserts”) and are often reported to lack candidate genes.
Most GWAS associations are attributable to variation in regula-
tory rather than coding sequence, with significant enrichment in
enhancers, and particularly super-enhancers—large enhancer clus-
ters that are usually cell type-specific and control expression of key
genes involved in cell state (Hnisz et al, 2013). Testing individual
candidate SNPs for effects on transcription—as a means of refining
disease-associated haplotypes to specific functional variants—would
bypass the limitations of LD and directly assay the process that
mediates disease risk, but was previously laborious and expensive.
The development of high-throughput assays of enhancer activity,
such as massively parallel reporter assays (MPRAs), has now made
this possible. MPRAs simultaneously test the regulatory activity of
large numbers of short sequences by coupling each to a barcoded
reporter gene (Melnikov et al, 2012). By normalising the RNA
barcode counts from transfected cells to their equivalent counts in
the input plasmid library, MPRAs have identified genetic variants
that modulate expression in various settings (Tewhey et al, 2016;
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Ulirsch et al, 2016). A key feature of MPRAs, however, is that the
results are determined by the transcription factors present within
the transfected cells, and so could be misleading if an inappropriate
cell type was used. To date, almost all MPRA studies have been
performed in cell lines, in part because these are easy to culture and
transfect. It is widely recognised, however, that these are poor
surrogates for the types of the immune cells that drive autoimmune
disease (Astoul et al, 2001; Bartelt et al, 2009).
Here, we adapt an MPRA for use in resting and stimulated
primary CD4 T cells—the cell type whose regulatory DNA is most
enriched for immune-mediated disease SNPs (Farh et al, 2015). By
simultaneously testing candidate SNPs from 14 immune disease-
associated gene deserts for expression-modulating activity, we
generate a basis for exploring the underlying biology that can yield
previously unappreciated insights into the effects of disease-asso-
ciated variation. At the pleiotropic 6q23 locus, for example we
uncover a molecular mechanism whereby a common variant—iden-
tified via its expression-modulating effect in CD4 T cells—disrupts
an NF-jB-driven pathway that normally limits T-cell activation
through the dynamic formation of a TNFAIP3 super-enhancer.
Disruption of this feedback circuit releases activated CD4 T cells
from an intrinsic molecular brake and reveals a mechanism by
which a multi-disease-associated haplotype can causally change
biology, and a pathway that would appear to be pervasively
involved in human autoimmune disease.
Results
Adaptation of MPRA for use in primary CD4 T cells
To determine whether causal variants could be identified via their
functional effects, we designed an MPRA to assess candidate SNPs
(all variants with r2 ≥ 0.8 with the lead SNP) at 14 gene deserts
linked to 10 immune-mediated diseases (Fig 1A, Table 1; Trynka
et al, 2011; Cooper et al, 2012; Eyre et al, 2012; Jostins et al, 2012;
Tsoi et al, 2012; International Genetics of Ankylosing Spondylitis C
et al, 2013; International Multiple Sclerosis Genetics C et al, 2013;
Liu et al, 2013; Onengut-Gumuscu et al, 2015). Several of these loci
cannot be resolved by fine-mapping (Farh et al, 2015; Huang et al,
2017). Gene deserts were selected because (i) less is known about
how these predispose to disease compared with regions containing
candidate genes, (ii) other non-coding mechanisms (such as splicing
effects) are unlikely to account for these associations, and (iii) many
of these contain epigenetic marks consistent with enhancer activity
(Hnisz et al, 2013). To maximise the genomic context tested around
each SNP, we designed three overlapping constructs for every SNP
allele (Ulirsch et al, 2016) and synthesised extra oligonucleotides to
test combinations of risk alleles if more than one SNP could be
assayed in the same construct. We also included oligonu-
cleotides that tiled each locus at 50 bp intervals to test for enhancer
activity—and enable us to exclude regions that lacked this.
After assembly, the MPRA plasmid library was transfected into
primary CD4 T cells from healthy donors (Fig 1A, Materials and
Methods) but no expression of the reporter gene was detected
(Appendix Fig S1A and B). After confirming that successful transfec-
tion had occurred (Appendix Fig S1B), we surmised that the mini-
mal promoter, which is conventionally used in MPRA, may be
insufficient to initiate transcription in primary T cells. In cell line-
based MPRA studies, stronger promoters have been shown to
produce highly comparable results to those obtained using a mini-
mal promoter (Ernst et al, 2016; Ferreira et al, 2016). We therefore
screened a series of promoters in CD4 T cells (Appendix Fig S1C)
and selected the Rous sarcoma virus (RSV) promoter for incorpora-
tion into an adapted MPRA vector (Fig 1B) as this robustly initiated
transcription but was not so strong as to preclude further amplifi-
cation.
After assembly, the adapted MPRA plasmid library was trans-
fected into resting and stimulated CD4 T cells from 12 healthy
donors. Multiple biological replicates (donors) were used to ensure
that the results were reproducible, and control for differences in
CD4 T cell composition between donors and the reduced dynamic
range expected with a stronger promoter. After 24 h, GFP was
detected and RNA was extracted to quantify barcode expression by
high-throughput sequencing (Appendix Fig S1D). After pre-proces-
sing, barcode counts were collapsed to individual genomic
constructs for analysis (Materials and Methods). Using principal
component analysis, we found that the activation state of T cells
was responsible for much of the total variance (Fig 1C) and that the
transcriptional activity of constructs—calculated by normalising
RNA barcode counts to their respective counts in the plasmid
library—correlated well between individuals (Fig 1D). To detect
expression-modulating variants, we used QuASAR-MPRA (Kalita
et al, 2018; Fig 2A) and combined the results from each donor using
a fixed-effects meta-analysis (Materials and Methods). Significant
expression-modulating activity was detected at one or more
constructs for 8/10 positive control SNPs (comprising five expres-
sion-modulating variants (Tewhey et al, 2016), two single variant
eQTLs (Farh et al, 2015) and three synthetic SNPs that included/
disrupted a canonical transcription factor binding site; Fig 2B).
Enhancer activity was also detected in the positive control regions
for the tiling analysis, while no such activity was detected in the
negative controls (Appendix Table S1, Materials and Methods). The
effects observed in resting and stimulated CD4 T cells were highly
correlated (Appendix Fig S1E), but these effects did not correlate
particularly well with results obtained in Jurkat cells (an
immortalised CD4 T-cell line)—reinforcing the value of using an
appropriate cellular model when studying human disease
(Appendix Fig S1F). To validate the observed effects, we tested the
most significant expression-modulating SNP at each haplotype, two
positive controls and five SNPs with no allele-specific effects using a
complementary luciferase-based system (Fig 2C). Despite using a
different promoter and quantification method, the MPRA and luci-
ferase results were highly correlated (Pearson r = 0.87)—indicative
of genuine expression-modulating effects that are likely to be physi-
ologically relevant (Fig 2D). To determine whether these variants
could have been prioritised by other means, we compared the
MPRA results with in silico methods designed to identify functional
variants—DeepSEA (Zhou & Troyanskaya, 2015) and RegulomeDB
(Dong & Boyle, 2019; Dataset EV1). Considering these approaches
together, the lead MPRA SNP was predicted to be the most function-
ally significant variant at 3/14 loci (2 by DeepSEA, 1 by Regu-
lomeDB). DeepSEA also predicted that 3 more lead SNPs would be
functionally significant, but prioritised other candidate SNPs at
these loci (most of which had no expression-modulating effect in
CD4 T cells). At the remaining eight loci, the lead MPRA SNP was
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not predicted to have an expression-modulating effect—consistent
with these methods being better at predicting negative effects than
positive effects (Dong & Boyle, 2019) and highlighting the value of
studying disease-associated loci in relevant primary cells. Alto-
gether, these data indicate that MPRA can be adapted for use in
primary CD4 T cells and that the results reflect the activation state
of the cells and can identify constructs with regulatory effects.
Adapted MPRA in CD4 T cells provides insights into the biological
effects of genetic associations
After establishing that MPRA could be performed in primary CD4 T
cells, we next examined the results at disease-associated loci
(Appendix Figs S2 and S3, Datasets EV2 and EV3). To assess
whether adapted MPRA would identify known causal variants, we
used an inflammatory bowel disease (IBD)-associated locus that has
been fine-mapped to a single variant, rs1736137 (Huang et al,
2017). In both resting and stimulated T cells, this SNP had highly
significant expression-modulating activity, with the IBD-risk allele
consistently increasing transcription (Fig 3A). As a further proof of
principle, we next examined an ankylosing spondylitis-associated
locus, where Bayesian fine-mapping using corrected coverage esti-
mates resolves the association to three SNPs in the 99% credible set
(rs6759298, rs4672505 and rs13001372). In stimulated T cells, one
of these SNPs (rs6759298) had the most significant expression-
modulating effect at this locus, while the others had negligible
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Figure 1. Development of MPRA for use in primary human CD4 T cells.
A Experimental workflow for MPRA: oligonucleotide library is cloned into an empty vector, and a reporter gene and promoter are inserted using restriction sites within
the oligonucleotide. The assembled plasmid is transfected into primary CD4 T cells, and RNA is extracted after 24 h. RNA barcode counts are normalised to their
respective counts in the input plasmid library (DNA), which is sequenced separately.
B Adapted MPRA plasmid incorporating RSV promoter.
C Principal component analysis of scaled element counts (sum of barcodes tagging same genomic construct in mRNA) in resting and stimulated CD4 T cells from 12
donors. Dotted lines indicate samples from the same donor.
D Heat maps showing pairwise comparison of MPRA activity for all constructs (mRNA/DNA) between donors—left panel: resting CD4 T cells; right panel: stimulated
CD4 T cells.
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We next investigated whether adapted MPRA could resolve
possible causal variants at other loci, and so provide testable
hypotheses into disease mechanisms. SNPs with strong functional
effects were identified at several loci (Appendix Figs S2 and S3),
including—for example—a chromosome six locus associated with
both IBD and multiple sclerosis. Of 44 candidate SNPs in the shared
risk haplotype, a single variant (rs34421390) had by far the largest
and most significant expression-modulating effect in both resting
and stimulated CD4 T cells (Fig 3C). This provides a focus for study-
ing the upstream biology and demonstrates that the risk haplotype
reduces transcription—an important finding since the locus interacts
with the promoter of JARID2, a component of the polycomb repres-
sive complex 2, in CD4 T cells (Javierre et al, 2016).
We made similar insights at a type 1 diabetes-associated locus,
which contains 38 SNPs in strong LD. At this haplotype, the largest
and most significant expression-modulating effect occurred with a
construct containing the risk alleles for two adjacent SNPs
(rs1988588 and rs3902659) which are 60 bp apart (Fig 3D). Both
SNPs had similar effects when tested individually (with the risk
allele reducing transcription) but these were weaker than with the
construct containing both risk alleles (Fig 3D). This raises the possi-
bility that the functional effect of this haplotype is mediated by a
synergistic interaction between two adjacent SNPs, rather than a
single causal variant—a prospect that could not be derived from
genetic data since the SNPs are in complete LD (r2 > 0.9999,
Onengut-Gumuscu et al, 2015). This provides a basis to study the
molecular mechanisms at this locus, which could help resolve the
underlying biology.
Altogether, these results show that MPRA in primary CD4 T cells
can identify SNPs that causally alter gene expression, and so
provide testable hypotheses into disease mechanisms, while simul-
taneously identifying the nature of the functional effect.
MPRA identifies an expression-modulating variant that disrupts
NF-jB binding and super-enhancer formation
To confirm that MPRA in primary CD4 T cells could help resolve
disease mechanisms, we selected a pleiotropic locus on chromo-
some 6 for further study (Fig 4A). This region was chosen for
several reasons. First, it was the only haplotype that was associated
with six different diseases (Table 1), highlighting the biological
importance of the locus. Second, despite receiving considerable
attention, there is still uncertainty regarding the causal gene, with
some studies implicating TNFAIP3, mainly because this is the clos-
est plausible candidate (Jostins et al, 2012; Onengut-Gumuscu et al,
2015; Calderon et al, 2019) while others suggest that IL20RA is
responsible (McGovern et al, 2016; Wu et al, 2019). Third, statisti-
cal fine-mapping has been attempted at this locus but has been












rs883220 – 1p34 RA 102.3 9 30.2
rs6759298 (AS)
rs10865331 (Ps)
0.86 2p15 AS, Ps 99.5 12 33.9
rs1534422 – 2p24 ATD 208.2 12 15.9
rs1813375 – 3p24 MS 203.9 15 10.9
rs2611215 – 4q32 T1D 139.4 20 16.7
rs12186979 – 5p13 AS 59.7 5 97.8
rs17119 – 6p23 UC, CD, MS 512.1 44 22.6
rs2327832 (SLE) rs6920220
(rest)a
0.92 6q23 RA, CeD, UC, CD,
SLEb, T1Dc
143.6 9 47.5
rs1991866 – 8q24 UC, CD 136.2 28 22.0
rs2456449 – 8q24 MS 219.3 17 19.5
rs4409785 – 11q21 ATD, vitiligod 181.2 3 9.7
rs1456988 – 14q32 T1D 1,086.9 38 14.0
rs1297258 – 21q21 UC, CD 274.0 38 24.1
rs2836883 (AS, PSC)
rs2836878 (UC, CD)
1.0 21q22 AS, PSC, UC, CD 87.1 13 5.8
AS, ankylosing spondylitis; ATD, autoimmune thyroid disease; CeD, coeliac disease; CD, Crohn’s disease; Chr., chromosome; MS, multiple sclerosis; Ps, psoriasis;
PSC, primary sclerosing cholangitis; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; SNP, single nucleotide polymorphism; T1D, type 1 diabetes; UC,
ulcerative colitis.
Genetic associations were identified from published immunochip data. For each locus, the extended haplotype (LD region tagged by all SNPs with r2 ≥ 0.8 and
extended by 50 bp on either side) does not contain coding or well-characterised non-coding genes. Haplotype block size represents region tagged by all SNPs
with r2 ≥ 0.8.
aCeD tag SNP rs17264332 (r2 = 1.0 with rs6920220).
bAssociation reported subsequently (Langefeld et al, 2017).
cAssociation reported using P < 1 × 105 to obtain a Bayesian posterior probability for T1D association given known associations with other diseases (Onengut-
Gumuscu et al, 2015).
dVitiligo association reported in GWAS, not immunochip (Jin et al, 2012).
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hampered by strong LD (Farh et al, 2015; Huang et al, 2017;
Fig 4B). In the MPRA, the same SNP (rs6927172) showed the stron-
gest expression-modulating effect in both resting and stimulated T
cells, with the risk allele consistently reducing transcription (Fig 4C,
Appendix Figs S2 and S3). Further examination of this SNP revealed
that it lies in a highly conserved region (Appendix Fig S4A) contain-
ing an experimentally validated NF-jB binding motif, to which all
NF-jB dimers can bind (Wong et al, 2011). rs6927172 is located at
position 10 within this 11-mer binding site, with the risk allele
predicted to disrupt binding (Fig 4D, Appendix Fig S4B). To deter-
mine whether allele-specific NF-jB binding might account for the
MPRA result, we transfected the MPRA plasmid library into CD4 T
cells, immunoprecipitated NF-jB and quantified the plasmids to
which it was bound. We confirmed that NF-jB differentially bound
to rs6927172-containing plasmids in a manner consistent with the
MPRA result and in silico prediction (Appendix Fig S4C). We next
investigated whether allele-specific NF-jB binding might also occur
at the native locus in primary CD4 T cells. To do this, we isolated
CD4 T cells from healthy donors who were heterozygous at
rs6927172 and immunoprecipitated NF-jB to quantify the relative
binding to each allele (Materials and Methods). We observed that in
stimulated T cells, NF-jB exhibited reduced binding to the
rs6927172 risk allele—consistent with the MPRA result (Fig 4E).
Conversely, we did not detect allele-specific binding in resting T
cells, which may reflect insufficient NF-jB signalling and suggests
that the MPRA result in resting cells could be partly due to the tran-
sient activation that can occur following nucleofection (Zhang et al,
2014).
To determine whether differential NF-jB binding might affect
enhancer strength, we exploited the fact that active enhancers are
transcribed, producing enhancer-(e)RNAs whose abundance gener-
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Figure 2. Allele-specific expression-modulating effects in CD4 T cells.
A qq plots of the observed log10(P) values versus the expected log10(P) values under the null hypothesis for representative resting and stimulated CD4 T-cell
samples.
B Activity of each allele at 10 positive control SNPs and 1 negative control SNP in stimulated T cells. GATA1, NF-jB and RUNX1 constructs were designed to include a
binding site for the indicated transcription factors (+) or with that site disrupted (). Fixed-effects meta-analysis P value is shown: * < 0.05; ** < 0.01, *** < 0.001,
**** < 0.0001. Box and whisker plots represent median and IQR (box) and min to max (whiskers). Exact P values are shown in Appendix Table S4.
C Experimental workflow for validation experiment using a different promoter (EF1a), reporter gene (luciferase) and quantification method (qPCR).
D Expression-modulating effect of each SNP [log2(OR)] as measured in MPRA and validation experiments. OR were calculated using the median activity of allelic
constructs and are presented with respect to the risk allele (luciferase: n = 5, MPRA: n = 12).
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Figure 3. MPRA in CD4 T cells identifies biological effects of disease associations.
A Pie chart depicting fine-mapping results (Huang et al, 2017; posterior probabilities) for an IBD-associated locus on 21q21 (left panel). MPRA results in resting (centre
panel) and stimulated CD4 T cells (right panel) showing that the putative causal variant has significant expression-modulating effect.
B Pie chart depicting Bayesian fine-mapping results for an AS-associated locus on 2p15 (left panel). MPRA results in stimulated T cells (right panel) showing that
rs6759298 has a significant expression-modulating effect (the strongest of any variant at this locus) while the other candidate SNPs have negligible effects.
C GWAS results (Liu et al, 2015) at a Crohn’s disease and multiple sclerosis-associated locus on 6p23 (left panel). MPRA for candidate SNPs in stimulated T cells (right
panel) identifying a SNP (rs34421390) with by far the greatest expression-modulating effect at this locus (blue, risk allele reduces expression; red, risk allele increases
expression). Dotted horizontal line represents significance threshold (corrected for multiple testing).
D GWAS results at a type 1 diabetes-associated locus on 14q32 (Onengut-Gumuscu et al, 2015; left panel). MPRA for the candidate SNPs in stimulated T cells (right
panel). The construct with the largest and most significant effect contains the risk alleles for 2 SNPs (rs1988588 and rs3902659), each of which has a smaller effect
when tested individually (position indicated by vertical dotted line). Dotted horizontal line represents significance threshold (corrected for multiple testing).
Data information: Box and whisker plots represent median and interquartile range (box) and min to max (whiskers). ****FDR-corrected meta-analysis P < 0.0001. Exact
P values are shown in Appendix Table S4.
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allele-specific expression assay, we compared the amount of eRNA
transcribed from each allele in stimulated heterozygous CD4
T cells—thus ensuring that external factors would affect both alleles
equally. We found that transcription of the eRNA was lower from
the risk allele, in which the NF-jB binding site is disrupted (Fig 4F).
This suggests that the disease-associated haplotype diminishes
enhancer activity by reducing NF-jB binding—potentially linking
the genetic association to a specific functional deficit.
During inflammatory responses, NF-jB binding has been
reported to direct dynamic super-enhancer formation (Brown et al,
2014). To better define the functional consequences of allele-specific
NF-jB binding at this locus, we performed H3K27 acetylation
(H3K27ac) ChIP-sequencing in stimulated CD4 T cells from major
and minor allele homozygotes at rs6927172. This facilitated a
genome-wide comparison of active regulatory regions and enabled
us to characterise the effect of rs6927172 on enhancer activity. We
observed consistently stronger enhancer activity at this locus in
major allele homozygotes compared with minor (risk) allele
homozygotes (Appendix Fig S5A). To improve peak-calling and
generate representative data sets, we combined the genotypic repli-
cates for subsequent analysis. Using the Rank Ordering of Super-
Enhancers (ROSE) algorithm (Whyte et al, 2013), we found that
rs6927172 was located within a 45.5 kb super-enhancer in major
allele homozygotes (Fig 4G, Appendix Fig S5A). This super-
enhancer appears to be T cell-specific and potentially activation-
specific, since it is also present in stimulated Th17 cells, but not in
27 other primary tissues nor in five other immune cell types (Hnisz
et al, 2013). Consistent with this, we found that many of the tran-
scription factors predicted to bind within the constituent elements of
the super-enhancer were involved in T-cell activation (Appendix Fig
S5B and C). In contrast to the strong enhancer activity in major
allele homozygotes, there was negligible enhancer activity at the
rs6927172 locus in minor allele homozygotes (Fig 4G, Appendix Fig
S5A). Indeed, while enhancer activity was detected 1.5 kb upstream
and 18.8 kb downstream of this SNP (extending to the 50 and 30
ends of the annotated super-enhancer), the overall enhancer
strength across this region was fourfold lower in the presence of the
risk allele, and super-enhancer formation was accordingly disrupted
(Fig 4G, Appendix Fig S5A).
To understand why disrupting the formation of an NF-jB-driven
super-enhancer might predispose to multiple immune-mediated
diseases, we next investigated the genes that it regulated. Using
available promoter capture Hi-C data from stimulated CD4 T cells,
we confirmed that the majority of super-enhancer interactions were
either with the promoter of TNFAIP3 or with a region ~ 41 kb down-
stream of TNFAIP3 that also interacts with the TNFAIP3 promoter
(Fig 4H). Consistent with this, we found that rs6927172 genotype
correlated with expression of TNFAIP3—but not other genes at this
locus—in CD4 T cells from patients with active IBD (Fig 4I). Expres-
sion of IL20RA, which was suggested to be causal based on experi-
ments in cell lines (McGovern et al, 2016; Wu et al, 2019), could
not be detected in primary CD4 T cells and is not expressed in
primary immune cells according to publicly available data sets
(Fernandez et al, 2016; Schmiedel et al, 2018; Appendix Fig S5D).
In contrast, TNFAIP3 is highly expressed in effector CD4 T cells
(Schmiedel et al, 2018; Appendix Fig S5E) and encodes A20, a key
negative regulator of NF-jB signalling and an early target gene of
NF-jB (Lee et al, 2000).
Collectively, these data are consistent with a model in which NF-
jB signalling in stimulated CD4 T cells leads to the formation of a
super-enhancer that upregulates a key NF-jB inhibitor—thereby
limiting inflammatory responses. This regulatory circuit can be
disrupted by a common expression-modulating variant, such that
NF-jB binding and enhancer activity are diminished in the presence
of the risk allele. This would be predicted to lead to excessive
inflammatory responses in CD4 T cells, consistent with the pleio-
tropic association with immune-mediated disease.
The NF-jB binding site disrupted by rs6927172 regulates TNFAIP3
expression and inflammatory responses in CD4 T cells
To test whether our proposed model was correct, we sought to
delete the NF-jB binding site in primary CD4 T cells using CRISPR-
Cas9. Efficient genome editing in primary T cells usually requires
the cells to be pre-activated (Hendel et al, 2015), but a method was
recently described for editing resting T cells (Seki & Rutz, 2018).
Since we wished to study the effects of editing upon subsequent T-
cell activation, we similarly optimised conditions for editing resting
T cells (Materials and Methods, Appendix Fig S6A and B). To reduce
the chance that an observed effect might be due to off-target activ-
ity, we designed several gRNAs that flanked the rs6927172-
containing NF-jB binding site and used these in different combina-
tions (Fig 5A). We achieved mean editing rates of 60–70% for three
of the four gRNA combinations, of which ~ 80% of predicted indels
ablated the NF-jB binding site (Fig 5B). Of note, the lower editing
rate observed with the fourth gRNA combination probably reflects
steric hindrance between Cas9-gRNA ribonucleoproteins (RNPs)
since the offset between gRNAs was only 4 bp (Ran et al, 2013).
We next investigated how deleting the NF-jB binding site would
affect transcription locally. After RNP nucleofection, CD4 T cells
were rested for 48 h for editing to occur and then stimulated for
24 h (Fig 5C, Materials and Methods). To specifically quantify RNA
that was transcribed during T-cell activation—and after editing—we
added 5-ethynyl uridine (EU) at the time of stimulation to facilitate
nascent RNA capture (Materials and Methods). RNA that incorpo-
rated this modified base was purified, and expression of protein-
coding genes within 1.5 Mb of the deletion site was measured and
normalised to a non-targeting control. Of the six genes tested, only
TNFAIP3 expression was significantly altered (Fig 5D). Moreover,
individual deletions of the other candidate SNPs within the disease-
associated super-enhancer did not significantly alter TNFAIP3
expression—consistent with dysregulation of enhancer activity
being specific to rs6927172 (Appendix Fig S6C).
To understand the biological consequences of this effect, we next
examined markers of T-cell activation. Using a fluorescently tagged
gRNA that is detectable by flow cytometry, we distinguished CD4 T
cells that contained RNPs (and were likely to have been edited)
from those that did not. Analysing these populations separately, we
observed a specific increase in CD69 expression, an early marker of
T-cell activation, in the RNP-containing cells, that was present not
in the non-targeting control, nor in RNP-negative cells from the
same transfection (Fig 5E). This indicated that deletion of the NF-jB
binding site, which is physiologically disrupted by rs6927172, leads
to increased T-cell activation.
To further explore the underlying mechanism, we used flow
cytometry to quantify IjBa phosphorylation, a key step in NF-jB
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signalling (Zandi et al, 1997). After normalising to the non-
targeting control, the increase in phospho-IjBa was found to
directly correlate with the overall editing efficiency (Fig 5F)—
suggesting that NF-jB signalling increases proportionally with
deletion of the NF-jB binding site. To understand how this would
affect CD4 T-cell effector function, we quantified cytokine produc-
tion and found that deletion of the NF-jB binding site increased
the production of effector cytokines from all major T helper cell
lineages, consistent with unrestrained inflammatory responses
(Fig 5G). Finally, to confirm that these results were indicative of
a TNFAIP3-dependent effect, we directly disrupted TNFAIP3 using
RNPs and showed that this phenocopied the observed effects,
with marked increases in T-cell activation (Appendix Fig S6D)
and effector cytokine production (Appendix Fig S6E), consistent
with the known role of A20 in regulating inflammation
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Collectively, these data identify an NF-jB-driven regulatory
circuit which constrains T-cell activation through the dynamic
formation of a super-enhancer that drives expression of TNFAIP3, a
key NF-jB inhibitor. In primary CD4 T cells, this circuit is
disrupted—and super-enhancer formation prevented—by the risk
variant at rs6927172, thus revealing the molecular and cellular
consequences of a pleiotropic disease association.
Discussion
A fundamental goal of GWAS was to better understand disease biol-
ogy (Visscher et al, 2017). As such, despite widespread success in
variant discovery, this goal remains unfulfilled—since we have not
yet transitioned from lists of associated SNPs to insights into disease
mechanisms. Here, we have adapted an MPRA to simultaneously
assess the functional effects of hundreds of non-coding genetic vari-
ants in primary CD4 T cells—the cell type whose regulatory DNA is
most enriched for immune-mediated disease SNPs (Farh et al,
2015). By analysing each SNP individually, this method bypasses
the limitations of LD and enables putative causal variants to be iden-
tified via their biological effects. Unlike fine-mapping, this approach
does not attempt to refine GWAS statistics and so does not provide
a specific estimate of causality for each SNP. However, by identify-
ing SNPs that causally change biology, this method can resolve the
functional consequences of disease-associated genetic variation and
provide a focus for studying disease mechanisms. Importantly, this
approach is broadly applicable and could be used to identify puta-
tive causal variants at any disease-associated locus that overlaps
with T-cell regulatory elements—even those that cannot be fine-
mapped—thus overcoming a major bottleneck in the transition from
genetic variants to disease mechanisms.
To illustrate the value of this approach, we used the MPRA
results as a basis for investigating disease mechanisms at a pleio-
tropic locus that has been linked to six different immune-mediated
diseases but cannot be fine-mapped. In doing so, we uncovered a
regulatory circuit that constrains T-cell activation through the
dynamic formation of TNFAIP3 super-enhancer and show how this
can be disrupted by a common, expression-modulating variant that
perturbs NF-jB binding—consistent with the known vulnerability
of super-enhancers to perturbation of their components
(Hnisz et al, 2013). Altogether, this identifies a biological mecha-
nism that is likely to be broadly involved in human autoimmune
disease. Indeed, while exuberant effector CD4 T-cell responses
have been implicated in the initiation and perpetuation of all of
the diseases linked to rs6927172 (Bluestone et al, 2015), evidence
of how common genetic variation might contribute to this has
previously been lacking.
A key strength of performing MPRA, and follow-up experiments,
in primary cells is that this provides greater confidence that the
results are physiologically relevant. For example, these data show
that in primary CD4 T cells, the biological effect of this multi-
disease-associated haplotype is solely mediated by TNFAIP3, and
not by any of the other genes at the locus. Several lines of evidence
support T cells as the relevant cell type for this association,
including the presence of a T cell-specific super-enhancer involving
the lead SNP (Hnisz et al, 2013) and the key role that T cells are
known to play in all the diseases linked to rs6927172 (Bluestone
et al, 2015). Moreover, a very recent study of chromatin accessibil-
ity identified an allele-specific effect of rs6927172 in stimulated CD4
T cells that was not detected in other immune cell types (Calderon
et al, 2019). By resolving the downstream consequences of this
effect—both on local transcription and, in turn, on T-cell
responses—we extend this observation and identify a mechanism
consistent with a broad predisposition to immune-mediated disease.
Of note, a similar mechanism was previously reported for a dif-
ferent locus that is located downstream of TNFAIP3 and associated
with SLE, but not with any the other diseases linked to rs6927172
(Adrianto et al, 2011). At this low frequency haplotype, which is
not in LD with rs6927172 (r2 = 0.001), the putative causal variant
also alters NF-jB binding and interacts with the TNFAIP3 promoter
(Adrianto et al, 2011). That two distinct disease-associated loci have
similar functional consequences highlights the importance of
TNFAIP3 in human autoimmunity and may point to cell type-
specific effects. For example, the SLE-only locus does not interact
with TNFAIP3 in stimulated CD4 T cells (Javierre et al, 2016) but
has strong enhancer activity in transformed B cells (Whyte et al,
2013)—a cell type linked to SLE pathogenesis and enriched for SLE-
associated variants (Farh et al, 2015).
This adapted MPRA is subject to the same limitations as regular
MPRA; in that, each construct is tested in a plasmid, out of its native
genomic context—reinforcing the importance of studying regions in
◀ Figure 4. MPRA in CD4 T cells identifies an expression-modulating variant that disrupts NF-jB binding and enhancer function.A IBD GWAS results (Liu et al, 2015) at a multi-disease-associated locus on chromosome 6q23.
B Fine-mapping results (Huang et al, 2017; posterior probabilities) for candidate SNPs at this locus.
C A single variant (rs6927172) has the largest and most significant expression-modulating activity in resting (left panel) and stimulated CD4 T cells (right panel) with
the risk allele reducing transcription. Plots represent median and IQR (box) and min to max (whiskers). FDR-corrected meta-analysis P value shown.
D Sequence logo for an experimentally validated NF-jB binding motif (Wong et al, 2011). The genomic sequence around rs6927172 is aligned below.
E Allele-specific NF-jB binding in CD4 T cells from rs6927172 heterozygotes, demonstrating reduced NF-jB binding to the risk allele following stimulation (n = 8; one-
sample t-test, two-tailed).
F Allele-specific expression of enhancer RNA in heterozygous CD4 T cells. DNA used for technical control (n = 6; paired t-test; two-tailed).
G Genome-wide H3K27ac ChIP-seq in stimulated CD4 T cells from major and minor allele homozygotes at rs6927172 (n = 6). Upper panels show input-normalised
H3K27ac signals plotted against enhancer rank. Super-enhancers are defined above the inflection point of the curve. Lower panels show H3K27ac reads from a major
(left) and a minor (risk) allele homozygote (right) in a 9 kb window around rs6927172.
H Promoter capture Hi-C plot depicting interactions of the 6q23 super-enhancer in stimulated CD4 T cells.
I Expression of genes on 6q23 in CD4 T cells from 131 patients with active IBD, stratified by rs6927172 genotype (qPCR; one-way ANOVA). Error bars represent SD.
Expression of IL20RA and IL22RAR2 not detected.
Data information: Data represent mean  SEM, unless indicated. *P < 0.05; **P < 0.01, ***P < 0.001, ****P < 0.0001. Exact P values are shown in Appendix Table S4.
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Figure 5. Deletion of the NF-jB binding site, disrupted by rs6927172, dysregulates TNFAIP3 expression and increases CD4 T cell activation.
A Location of gRNAs flanking the NF-jB binding site (highlighted).
B Primary CD4 T-cell editing efficiency for indicated combinations of 50 and 30 gRNAs (n = 6 for DB, DH and FH and n = 2 for FB). Distribution of indels assessed using
ICE.
C Experimental workflow: equimolar amounts of 50 and 30 gRNA-containing RNPs (fluorescently tagged with ATTO-550) were nucleofected into resting CD4 T cells,
which were stimulated after 48 h with anti-CD2/3/28 microbeads and IL-2.
D Expression of genes on 6q23 in EU-containing mRNA (EU added at time of stimulation) showing that deletion of the NF-jB binding site specifically reduces
transcription of TNFAIP3, but not other genes at this locus (n = 6; one-sample t-test). Representative data from the DH gRNA combination.
E Expression of CD69, an activation marker, following CRISPR editing with indicated gRNA combinations or the non-targeting (negative) control (NTC)—data shown for
ATTO-550 positive (RNP-containing) and negative cells (n = 6; paired t-test, one-tailed). Inset flow cytometry plot depicting representative gating of ATTO-550-positive
and ATTO-550-negative cells.
F Correlation between editing efficiency (total indel rate) and levels of phosphorylated IjBa in CD4 T cells (normalised to the mean fluorescence intensity in NTC; n = 9,
linear regression).
G Secretion of effector cytokines following deletion of the NF-jB binding site—Th1 (left panel, IFNc), Th17 (centre panel, IL-17A) and Th2 subsets (right panel, IL-4;
n = 6, paired t-test, one-tailed).
Data information: Data represent mean  SEM. *P < 0.05; **P < 0.01; ****P < 0.0001. Exact P values are shown in Appendix Table S4.
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relevant cells. Extending MPRA to other primary cell types, particu-
larly to study disease-specific loci, is a logical next step. These data
also highlight the value of considering MPRA results as hypotheses to
be experimentally tested, rather than as definitive insights into isola-
tion. Indeed, we show that using multiple biological replicates adds
considerable power to identify expression-modulating effects, and so
characterising the functional consequences of any result is essential.
In summary, we have developed a scalable method that can distil
disease-associated haplotypes down to specific functional variants
in relevant primary cells, thereby generating testable hypotheses
into disease mechanisms—even within gene deserts—while over-
coming some of the limitations of statistical fine-mapping. This can
provide important insights into disease biology and represents a
framework by which much of the potential of GWAS in immune-
mediated disease could finally be realised.
Materials and Methods
Locus selection and library design
Fourteen loci were selected from immunochip studies in 10 immune-
mediated diseases. Inclusion criteria: no coding or well-characterised
non-coding genes in the extended haplotype (tagged by SNPs with
r2 > 0.8 with the lead variant and extended by 100 bp each side).
Oligonucleotides were designed to test every candidate SNP and tile
each locus at 50 bp intervals. Sliding windows were used for allelic
constructs, so that 1/3, 1/2 and 2/3 of the construct were 30 of the
variant, as described previously (Ulirsch et al, 2016). If adjacent
SNPs were within 114 bp, extra oligonucleotides were synthesised to
test combinations of risk alleles. Allelic constructs were tagged by 30
unique 11nt barcodes and tiling constructs by six unique barcodes.
Ten positive control SNPs were included: five expression-modulating
variants (Tewhey et al, 2016), two single variant eQTLs (Farh et al,
2015) and three synthetic SNPs (designed to include/disrupt a
known binding motif: GATA1/3 motif = TGATAG; RUNX1
motif = TGTGGTTT; NF-jB motif = GGGGGAATCCC). For the tiling
analysis, 2 kb control regions were used (positive = T-cell super-
enhancers: chr21:36421330-36423329, chr1:198626200-198628199;
negative = gene deserts with no enhancer activity: chr4:29562525-
29564524, chr4:34780413-34782412, hg19). In total, 99,990 170 bp
oligonucleotides were synthesised (Twist Biosciences) to contain the
16nt universal primer ACTGGCCGCTTCACTG, 114nt genomic
sequence, KpnI | XbaI restriction sites, an 11nt barcode and the 17nt
universal primer AGATCGGAAGAGCGTCG.
Oligonucleotide library cloning
Oligonucleotides were amplified by emulsion PCR (Micellula DNA
Emulsion & Purification Kit, Chimerx) using primers containing SfiI
restriction sites. 200 ng of the amplified library was digested with
SfiI (NEB) and cloned into SfiI-digested pGL4.10M vector. Resulting
plasmids were purified (Plasmid Plus Maxi kits, Qiagen), quantified
(Nanodrop 1000, Thermo Fisher) and sequenced to check barcode
representation. 2 lg purified plasmids were digested (KpnI/XbaI,
NEB) and ligated with a KpnI/XbaI-digested fragment containing a
promoter and EGFP (promoters: minimal promoter, SV40 (from
CBFRE-EGFP), RSV (from pRSCgfp-hAIM2) and EF1a (from
pOTTC407-pAAV EF1a eGFP)). Ligation products were transformed
into Escherichia coli, purified and quantified, as described. The
resulting MPRA plasmid library was sequenced (MiSeq) to confirm
barcode representation.
CD4 T-cell purification, transfection and cell culture
Source Leukocytes, purified from healthy donors, were obtained
from Massachusetts General Hospital (MGH) Blood Transfusion
Service. Peripheral blood mononuclear cells were isolated by density
centrifugation (Histopaque 1077, Sigma) and CD4 T cells positively
selected, as described previously (Lee et al, 2011). Purity was con-
firmed by flow cytometry (> 95%). CD4 T cells were split 2:1 for
immediate nucleofection (resting) or stimulation. Stimulation was
performed for 4 days using recombinant human IL-2 (10 ng/ml,
PeproTech) and Anti-Biotin MACSiBead Particles loaded with CD2/
3/28 antibodies (bead-to-cell ratio 1:2, Miltenyi). A minimum of six
technical replicates (nucleofections) were performed per sample.
Each replicate: 5 lg vector, 5 M CD4 T cells, 100 ll “1 M” nucleofec-
tion solution (Chicaybam et al, 2013), Nucleofector 2b program
V024 (resting T cells) or T023 (stimulated T cells). After nucleofec-
tion, 500 ll pre-warmed media was added to the cuvette and cells
were transferred to a 6-well flat-bottomed plate (final volume 5 ml/
well) and cultured at 37°C, 5% CO2. Cell culture media: IMDM
(Thermo Fisher), 20% FBS (Thermo Fisher), 1% non-essential
amino acids (Thermo Fisher), 2 mM GlutaMAX (Thermo Fisher) and
1% sodium pyruvate (Thermo Fisher). No antibiotics were used.
24 h after nucleofection, cells were harvested, pooled and lysed in
RLT Plus buffer (Qiagen).
Jurkat culture and transfection
Jurkats (Clone E6-1) were cultured in RPMI-1640, 10% FBS
(Thermo Fisher), 1% non-essential amino acids (Thermo Fisher),
2 mM GlutaMAX (Thermo Fisher) and 1% sodium pyruvate
(Thermo Fisher). No antibiotics were used. Transfections were
performed at rest or following stimulation (conditions as for CD4 T
cells). Nucleofection conditions: 2 lg vector, 1 M Jurkats, 100 ll
Amaxa Cell Line Nucleofector V solution and program X001. Cells
were harvested, pooled and lysed after 24 h.
Flow cytometry
CD4 T-cell purity, composition and transfection efficiency were
assessed by flow cytometry (BD LSR II). Purity and composition
panel (stained in 250 ll): CD4 APC (#357408), CCR4 BV421
(#359414), CCR6 AF700 (#353434), CD3 FITC (#300306), CD62L
PerCP/Cy5.5 (#304824), CXCR3 PE/Dazzle 594 (#353736) and
CD45RA PE/Cy7 (#304126)—all used at 1:100 dilution (all BioLe-
gend), Zombie Aqua Fixable Viability Kit (BioLegend) and Fc recep-
tor blocking reagent (Miltenyi). Transfection efficiency panel: EGFP,
CD4 APC (as above), Zombie Aqua Fixable Viability Kit, Fc receptor
blocking reagent. Data were gated using FlowJo v10 (BD).
Library preparation
Lysates were DNA depleted (gDNA eliminator column, Qiagen), and
RNA was extracted using a RNeasy Plus micro kit (Qiagen). For
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library preparation, 1 lg RNA was treated with TURBO DNAse
(Thermo Fisher) and reverse transcribed (SuperScript IV VILO,
Thermo Fisher). DNA removal was confirmed by qPCR. Sequencing
libraries were prepared by PCR (30 cycles) using PfuUltra II poly-
merase (Agilent) and custom primers that annealed to a 30 site
within EGFP (F) and the 30 universal primer site in the oligonu-
cleotide (R). Amplified libraries were cleaned using AMPure XP
beads (Beckman Coulter): 0.6×, 1.6× and 1.0×. Four sequencing
libraries were made from the input MPRA plasmid library (50 ng
vector, 18 PCR cycles). Libraries were sequenced in pools of 6 (Illu-
mina HiSeq2500, 50 bp, single-end reads).
Primers
Primer sequences are provided in Appendix Table S2.
MPRA analysis
Pre-processing
Barcode counts were obtained from FASTQ files after quality control
(FastQC). To be counted, a sequenced barcode had to match an
oligonucleotide barcode and be followed by ≥ 10 bases of the
expected constant sequence. To be a successful transfection, ≥ 70%
of the barcode library had to be represented. Raw count data were
normalised (CPM) and filtered to remove barcodes with median
CPM < 0.5 in RNA or DNA samples. Barcode counts for identical
constructs were then collapsed (summed) and quantile normalised.
Principal component analysis
Principal component analysis (PCA) was performed on pre-
processed data from RNA samples using the prcomp function in R.
The data were centred and scaled to have unit variance, and then,
singular value decomposition was performed. No components were
omitted.
Pairwise correlation analysis
The transcriptional activity of each construct was calculated by
dividing the normalised construct-level count (mRNA) by the
median count from the same construct in the input library (DNA).
Correlation matrices were created using the cor function (Pearson
correlation) in R.
Tiling analysis
To measure enhancer activity, we used the sharpr2 package (Wang
et al, 2018) in R. This was used because (i) the tiled regions were of
different sizes, (ii) the offset between constructs (50 bp) was not a
factor of the length of genomic sequence (114 bp), and (iii) we
could include reference allele SNP constructs to improve genomic
coverage. After removing alternate allele constructs, the median
counts for the remaining constructs in RNA and DNA were anal-
ysed. The regulatory scores for each region were based on standard-
ised log(RNA/PLASMID), and a regional FWER cut-off (0.05) was
used to identify high-resolution driver elements indicative of
enhancer activity.
SNP analysis
For the SNP analysis, we used QuASAR-MPRA (Kalita et al, 2018)
in the QuASAR package in R. After removing enhancer constructs,
964/970 SNP constructs were available for analysis. As this can only
analyse one sample at a time, a standard fixed-effect meta-analysis
was used to combine the results for biological replicates. To do this,
we used the logit transformation of the proportion of reference reads
in RNA (bl) and the standard error of this estimate (rbl ). We then
calculated logit transformation of the proportion of reference reads
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FDR correction for multiple testing was applied (Benjamini &
Hochberg, 1995).
Luciferase-based validation
The allelic constructs for the lead MPRA SNP at each locus were
synthesised as geneblocks with flanking restriction sites (50 KpnI, 30
BamHI; IDT). For one haplotype (14q32), the sequence was too GC
rich for synthesis and so was PCR amplified from a major allele
homozygote and site-directed mutagenesis used to make the alter-
nate allele construct (Q5 Site-Directed Mutagenesis Kit, NEB). Addi-
tional geneblocks for two positive controls and five SNPs with no
expression-modulating activity were synthesised (IDT). Geneblocks
were digested (KpnI/BamHI) and ligated into a custom Firefly luci-
ferase vector (VectorBuilder) to lie proximal to the luciferase
promoter (EF1a). The ligation product was transformed into E. coli,
sequenced to confirm geneblock insertion (Genewiz) and purified.
For each geneblock, equimolar amounts of the Firefly vector and a
custom Renilla luciferase vector (total 5 lg vector) were nucleo-
fected into resting CD4 T cells. DNA and RNA were extracted after
24 h. 200 ng RNA was DNAse treated (TURBO DNase, Thermo
Fisher) and reverse transcribed (SuperScript IV VILO, Thermo
Fisher). Quantification of Firefly and Luciferase genes was
performed in triplicate using qPCR. The results were normalised
using an adapted Delta-Delta-Ct method in which the Cts for Firefly
and Renilla (mRNA) were first normalised to their respective DNA
Cts (to control for any imbalance in the input mix) and then each
Firefly Delta-Ct was normalised to the Renilla Delta-Ct (to control
for transfection efficiency)—producing a measure of expression-
modulating activity. The activities of reference and alternate alleles
were compared to determine the SNP effect. Five biological repli-
cates were performed.
Fine-mapping ankylosing spondylitis (AS) association on 2p15
AS summary statistics (International Genetics of Ankylosing
Spondylitis C et al, 2013) were obtained from the GWAS catalog,
and SNPs in chr2:62518445..62618445 (hg19) were extracted.
Approximate Bayes factors summarising the association at each
SNP, and thus the posterior probabilities for each SNP being causal,
12 of 17 EMBO Molecular Medicine 12: e12112 | 2020 ª 2020 The Authors
EMBO Molecular Medicine Christophe Bourges et al
were calculated (Wakefield, 2009)—assuming a single causal vari-
ant model. The 99% credible set contained four SNPs. Recent work
has shown that this method can be biased (Hutchinson et al, 2020)
and so we used the corrcoverage R package to correct any bias, iden-
tifying a 99% credible set containing three SNPs: rs6759298,
rs4672505 and rs13001372 (corrected coverage 99.2%).
NF-jB binding site analysis
A common NF-jB motif was identified from protein-binding
microarray data (Additional File 2 from Wong et al, 2011). In brief,
the z-scores for the affinity of nine NF-jB dimers for each 11-mer
sequence were combined using Stouffer’s method to calculate the
statistical significance of the overall binding. After Bonferroni
correction, 100 statistically significant 11-mer sequences were iden-
tified (Padjust < 0.05) which had positive z-scores for every dimer.
These sequences were used to generate a common NF-jB motif logo
using WebLogo (Crooks et al, 2004).
NF-jB immunoprecipitation following MPRA
library nucleofection
CD4 T cells were purified and nucleofected with the MPRA plasmid
library, as described (n = 4). After 24 h, cells were harvested, resus-
pended in fresh media (106 cells/ml) and cross-linked (37% Formalde-
hyde to final concentration 1% for 10 min). This was then quenched
with glycine (final concentration 0.125 M) for 5 min. After washing,
cell pellets lysed for 10 min in lysis buffer with Complete Mini EDTA-
free Protease Inhibitor (Roche). Lysis buffer: 50 mM HEPES pH 7.9,
140 mM NaCl, 1 mM EDTA pH 8.0, 10% v/v Glycerol, 0.5% v/v
IGEPAL CA-630, 0.25% v/v Triton X-100. Two cycles of sonication
were performed (Bioruptor Pico, Diagenode) to remove contaminants
without chromatin shearing. Triton X-100 and NaCl were added to
final concentrations of 1% and 100 mM, respectively. 10 lg of sheared
chromatin were cleared by centrifugation (21,000 g, 10 min, 4°C), and
immunoprecipitation was performed overnight at 4°C using an anti-
NFkBp65 antibody (1:100, clone D14E12; Cell Signaling) or an isotype
control (1:500, rabbit IgG, Abcam; ab172730) with the SimpleChIP
Plus kit (Cell Signaling). Sequencing libraries were prepared as
described earlier (26 PCR cycles).
Allele-specific NF-jB ChIP
A 100 ml blood sample was obtained from eight healthy individuals,
heterozygous at rs6927172—identified via the NIHR BioResource.
All participants provided written informed consent. Ethical approval
was provided by the Cambridgeshire Regional Ethics Committee
(REC:08/H0308/176). All experiments conformed to the principles
set out in the WMA Declaration of Helsinki and the Department of
Health and Human Services Belmont Report. CD4 T cells were puri-
fied and left resting or stimulated for 4 days, before harvesting,
cross-linking, quenching and lysing, as described. After washing
(wash buffer: 10 mM Tris-HCl pH 8.0, 200 mM NaCl, 1 mM EDTA
pH 8.0, 0.5 mM EGTA pH 8.0), nuclei were resuspended in 200 ll
shearing buffer/107 cells and sonicated for nine cycles (30 s ON/
30 s OFF) using a Bioruptor Pico (shearing buffer: 0.1% w/v SDS,
1 mM EDTA, 10 mM Tris-HCl pH 8.0). Triton X-100 and NaCl were
added as described earlier. NF-jB ChIP was performed as described.
To assess for allele-specific binding, the NF-jB-bound DNA was
genotyped for rs6927172 in triplicate (TaqMan) alongside pre-mixed
DNA from a minor and a major allele homozygote at rs6927172. A
series of ratios of minor:major allele homozygote DNA were used
(from 4:1 to 1:4) to create a standard curve, against which the ratios
obtained in the NF-jB ChIP samples were compared.
Allele-specific eRNA analysis
DNA and RNA were extracted from stimulated CD4 T-cell lysates
(non-nucleofected). Genotyping was performed to identify 6 ×
rs6927172 heterozygotes. RNA was TURBO DNase-treated and
reverse-transcribed as described earlier. Nested PCR was performed
to amplify the region around rs6927172 from genomic DNA and
cDNA. PCR amplicons were gel-purified (Zymoclean Gel DNA
Recovery Kit, Zymo) and diluted to 8 ng/ll. 8 ng (5:1 insert:vector
ratio) was ligated into a Zero Blunt TOPO vector (Thermo Fisher)
and transformed into E. coli. For each sample, 96 colonies were
genotyped to quantify allelic ratios.
H3K27ac ChIP-seq and analysis
A 100 ml blood sample was obtained from three major and three
minor allele homozygotes at rs6927172—identified via the NIHR
BioResource. CD4 T cells were purified and stimulated for 4 days,
before harvesting, cross-linking, quenching, lysing and nuclei shear-
ing as described. 2% input samples were stored prior to immunopre-
cipitation, which was performed overnight at 4°C with an anti-
H3K27ac antibody (1:250, Abcam; ab4729) or an isotype control
(1:500, rabbit IgG, Abcam; ab172730) using the SimpleChIP Plus kit.
50 ng of immunoprecipitated DNA or input sample was used for
library preparation (10 amplification cycles, iDeal Library Preparation
kit, Diagenode). Libraries were sequenced in pools of 8, with each
pool sequenced in two lanes of an Illumina HiSeq2500 high output
flow-cell (50 bp, single-end reads): median 50.4 M reads (H3K27ac
ChIP) and 79.6 M reads (input). Sequencing reads were trimmed
using TrimGalore! (Phred score 24), filtered to remove reads < 36 bp
and aligned to the human genome (hg19) using Burrows-Wheeler
Aligner (BWA). Aligned reads were converted to BAM files, sorted
and technical duplicates merged before indexing using SAMtools (Li
et al, 2009). PCR duplicates and unmapped reads were removed, and
the resulting BAM files were re-sorted and indexed. For visualisation
in IGV, bigwig files were generated using bamCoverage (deepTools2).
Biological replicates were merged using SAMtools, and peaks were
called using MACS2 (Feng et al, 2012) after downsampling the input
files to the size of the H3K27ac files. MACS peaks were used for
super-enhancer identification using Rank Ordering of Super-Enhan-
cers (ROSE; Whyte et al, 2013) with a stitching distance of 12,500 bp
and a promoter exclusion zone  2,000 bp. For the minor allele
homozygote samples, activity at the super-enhancer locus was calcu-
lated by summing the activity of detected enhancers within the region
and normalising for region size.
In silico transcription factor binding analysis
Transcription factor binding motifs enriched at constituent elements
within the 6q23 super-enhancer were identified using TRAP (multi-
ple sequences; Thomas-Chollier et al, 2011), with all human
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promoters as the reference and an FDR correction for multiple test-
ing (Benjamini & Hochberg, 1995). Motifs were obtained from the
JASPAR CORE vertebrate database. Pathway analysis of enriched
transcription factors within KEGG pathways was performed using g:
Profiler (https://biit.cs.ut.ee/gprofiler/gost) with an FDR correction
(Benjamini & Hochberg, 1995).
Promoter capture Hi-C analysis
Interactions of the 6q23 super-enhancer in stimulated CD4 T cells
were identified from existing promoter capture Hi-C data (Javierre
et al, 2016) using the capture Hi-C plotter (https://www.chicp.org).
qPCR in CD4 T cells from inflammatory bowel disease patients
131 patients with active IBD were recruited before treatment (Lee
et al, 2011; Biasci et al, 2019). All patients provided written
informed consent, and ethical approval was provided by the
Cambridgeshire Regional Ethics committee (REC:08/H0306/21).
Experiments conformed to the principles set out in the WMA Decla-
ration of Helsinki and the Department of Health and Human
Services Belmont Report. CD4 T cells were positively selected from
a 100 ml blood sample, as described earlier. Cells were immediately
lysed, and RNA and DNA were extracted (AllPrep DNA/RNA Mini
kit, Qiagen). Genotyping was performed using the Illumina Huma-
nOmniExpress 12v1.0 BeadChip, and data were processed as previ-
ously described (Peters et al, 2016). qPCR for genes at the 6q23
locus was performed in triplicate on a Roche LightCycler 480, using
exon-spanning primers, with beta-actin as a reference (QuantiFast
SYBR Green PCR Kit; Qiagen).
CRISPR-Cas9 editing in resting CD4 T cells
Guide RNAs
gRNA sequences are provided in Appendix Table S3.
Optimisation
For RNP-based CRISPR editing in resting CD4 T cells, the following
conditions were tested: nucleofection buffer (Human T cell Nucleo-
fector kit, Lonza; “1 M” nucleofection solution), program (U014;
V024) and use of electroporation enhancer (IDT). Positive control
gRNAs: HPRT, CXCR4. Non-targeting controls: Alt-R CRISPR-Cas9
Negative Control crRNA #1 and #3 (IDT). To generate functional
sgRNA duplexes, crRNAs and tracrRNA (Alt-R CRISPR-Cas9
tracrRNA, ATTOTM 550) were reconstituted in duplex buffer
(200 lM), mixed 1:1 and heated to 95°C for 10 min before slowly
cooling. Cas9 RNPs were generated immediately before use by
adding Cas9 (Alt-R S.p. HiFi Cas9 Nuclease V3, 61 lM; IDT) to the
gRNA duplex in a 1:3 ratio and incubating at 37°C for 20 min. 5 ll
Cas9 RNP was nucleofected into 1 M CD4 T cells (positively selected
from fresh single leucocyte cones; National Blood Service,
Cambridge, UK) in 100 ll nucleofection buffer (program V024).
Electroporation enhancer was added where indicated (final concen-
tration 4 lM). After nucleofection, 500 ll pre-warmed media was
added and cells were transferred to a 24-well flat-bottomed plate (to-
tal volume 1 ml/well) and cultured at 37°C, 5% CO2. Cell culture
media: X-VIVO15 (STEMCELL), 5% FBS, 50 lM 2-mercaptoethanol,
and 10 lM N-acetyl L-cystine. After 6 h, the media was changed and
fresh pre-warmed media containing low dose IL-7 (1 ng/ml; Pepro-
Tech) was added to promote T-cell survival without stimulation.
48 h after nucleofection, cells were stimulated with anti-Biotin
MACSiBead Particles loaded with CD2/3/28 antibodies (bead-to-cell
ratio 1:2, Miltenyi) and IL-2 (10 ng/ml). Cells were harvested 24 h
after stimulation and used for flow cytometry or lysed. Surface
expression of CXCR4 was assessed by flow cytometry (stained in
250 ll): CXCR4 APC (1:100, #306510, BioLegend), Zombie Aqua
Fixable Viability Kit (Biolegend) and Fc receptor blocking reagent
(Miltenyi). Viability was ~ 80% at the end of the experiment.
Editing efficiency assessment
DNA and RNA were extracted from cell lysates as described. For
optimisation experiments, editing efficiency was estimated using a
T7 Endonuclease assay (IDT). An additional Proteinase K incubation
was used to inactivate T7 endonuclease I before fragment analysis.
Digested heteroduplexes were quantified using a Bioanalyzer 2100
(Agilent). The optimal conditions for RNP nucleofection in resting
CD4 T cells were 1 M buffer and V024 program, with electropora-
tion enhancer. These conditions were used for subsequent experi-
ments, in which editing efficiency was estimated using ICE
(Inference of CRISPR Edits, Synthego; preprint: Hsiau et al, 2019)—
a method that mathematically infers the composition of indels using
Sanger sequencing traces from edited and non-edited samples.
Deletion of NF-jB binding site at rs6927172 locus
gRNAs flanking the rs6927172-containing NF-jB binding site were
designed (http://crispr.mit.edu) and checked for suitable on- and
off-target activity (GPP sgRNA design tool: https://portals.broadinsti
tute.org/gpp/public/analysis-tools/sgrna-design). Two gRNAs prox-
imal (50) to the NF-jB motif (termed D and F) and two distal (30)
gRNAs (termed B and H) were synthesised (IDT). To reduce the
chance that an effect might be due to off-target activity, RNPs were
used in different combinations (one 50 gRNA RNP with one 30 gRNA
RNP). Predicted indels: DB, 33 bp; DH, 50 bp; FB, 18 bp; FH, 35 bp.
5 ll Cas9 RNP (either equimolar amounts of 50 and 30 gRNA-
containing RNPs or a non-targeting control) were nucleofected with
1 ll electroporation enhancer into resting CD4 T cells as described.
For nascent RNA capture experiments, 5-ethynyl uridine (EU, Click-
iTTM Nascent RNA Capture Kit, Thermo Fisher Scientific) was added
at the time of stimulation (final concentration 0.4 mM). 24 h later,
the supernatant was frozen for cytokine analysis, and the cells were
harvested for flow cytometry or lysed. Six biological replicates were
performed, although the RNP combination (FB) with very low edit-
ing efficiency was not repeated after the first two replicates.
Deletion of other candidate SNPs in the 6q23 super-enhancer
gRNAs flanking other candidate SNPs within the 6q23 super-
enhancer were designed, synthesised and incorporated into gRNA-
Cas9 RNPs as described earlier. An equimolar mix of 50 and 30 RNPs
were nucleofected into resting CD4 T cells, which were stimulated
48 h later and EU added, as described. After 24 h, cells were
harvested, and DNA and RNA were extracted.
Editing of TNFAIP3
Two gRNAs targeting TNFAIP3 were obtained from the Brunello
genome-wide CRISPR library (Doench et al, 2016) and synthesised
(IDT). RNPs for each gRNA were generated and nucleofected into
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resting CD4 T cells. After 48 h, cells were stimulated, and 24 h later,
the supernatant was frozen for cytokine analysis, and the cells
harvested for flow cytometry.
Flow cytometry
Surface staining was performed in 250 ll using CD69 BV421 anti-
body (1:100, #310930, BioLegend), Zombie Aqua Fixable Viability
Kit (Biolegend) and Fc receptor blocking reagent (Miltenyi). ATTO-
550 staining (ATTO-550-conjugated tracrRNA) was used to identify
cells containing the RNP. Intracellular staining (for experiments in
which the rs6927172-containing NF-jB binding site was deleted)
was performed using the eBioscience Foxp3 Staining kit (Thermo
Fisher) and a Phospho-IkB alpha (Ser32, Ser36) eFluor660 anti-
body (1:50, #12-9035-42, Thermo Fisher) with a fluorescence-
minus-one control.
Nascent RNA capture
Following RNA extraction, EU-labelled RNA was biotinylated and
purified using Dynabeads Streptavidin T1 magnetic beads (Click-iT
Nascent RNA Capture Kit, Life Technologies). Reverse transcription
was performed using bead-bound RNA (SuperScript VILO cDNA
synthesis kit), and qPCR was performed in triplicate (QuantiFast
SYBR Green; Qiagen) on a Roche LightCycler 480 with beta-actin as
reference gene. Expression of target genes was normalised to the
non-targeting control.
Cytokine quantification
For experiments in which the rs6927172-containing NF-jB binding
site was deleted, supernatant cytokines were quantified in duplicate
by electrochemiluminescence (MesoScale Discovery Immunoassay).
For experiments in which TNFAIP3 was directly edited, cytokines
were quantified in triplicate using Quantikine ELISAs (R&D).
Statistical methods
Statistical methods used in MPRA analysis are described above. For
other analyses, comparison of continuous variables between two
groups was performed using a paired t-test or one-sample t-test
when comparing against a hypothetical value. A Shapiro–Wilk test
was used to confirm normality, and sample sizes were based on
having 80% power to detect a standardised effect size of 2, a = 0.05
(and corrected for multiple testing as described). Two-tailed tests
were used as standard unless a specific hypothesis was being tested.
Data availability
The data sets produced in this study, including raw and processed
files, are available in the following databases:
• MPRA data: Gene Expression Omnibus GSE135925 (https://www.
ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE135925).
• ChIP-Seq data: Gene Expression Omnibus GSE136092 (https://
www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE136092).
Expanded View for this article is available online.
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The paper explained
Problem
Genome-wide association studies (GWAS) have identified hundreds of
regions of the human genome that are involved in the pathogenesis
of immune-mediated diseases, but the mechanisms by which these
loci drive disease remain largely unknown. Identifying causal variants,
whose biological effects mediate disease risk, is an important first step
but fine-mapping efforts have been frustrated by strong linkage dise-
quilibrium (LD), leaving most loci unresolved and the potential of
GWAS unfulfilled.
Results
This study describes the development of an adapted massively parallel
reporter assay for use in primary CD4 T cells—the cell type whose
regulatory DNA is most enriched for immune-mediated disease SNPs.
By using this method to study gene deserts linked to a range of
immune-mediated diseases, we simultaneously resolve the functional
consequences of hundreds of non-coding candidate SNPs and show
how this can identify putative causal variants via their functional
effects. We illustrate the power of this approach using a locus linked
to six autoimmune diseases that cannot be fine-mapped. By investi-
gating the lead expression-modulating SNP, we uncovered an NF-jB-
driven regulatory circuit which constrains T-cell activation through
the dynamic formation of a super-enhancer that upregulates TNFAIP3
(A20), a key NF-jB inhibitor. In activated T cells, this circuit is
disrupted—and super-enhancer formation prevented—by the risk
variant at the lead SNP, thus uncovering a mechanism that appears
to broadly predispose to human autoimmunity.
Impact
Our work provides a generalisable method that can distil disease-
associated haplotypes down to specific functional variants, via their
biological effects in disease-relevant primary cells. This generates
testable hypotheses into disease mechanisms and could be applied to
any non-coding association that overlaps regulatory elements in T
cells, including those that cannot be fine-mapped. This can provide
insights into disease biology, and a framework by which the consider-
able potential of GWAS in immune-mediated disease could finally be
realised.
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